ERBB2 and breast cancer: 20% of breast cancers are HER-2+, leading to a constant activation of HER-2 and its downstream pathways, namely PI3K/AKT and RAS/RAF/MEK/MAPK, which are involved in proliferation and cell death escape mechanisms [128].